ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0980

Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort

Jiayi Zheng1, Nevena Barjaktarovic2 and Liangjing lu3, 1Washington University School of Medicine, St. Louis, MO, 2The Wright Center for Community Health, South Abington Township, PA, 3Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)

Meeting: ACR Convergence 2024

Keywords: Administrative Data, Biologicals, Environmental factors, Epidemiology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Ambient air pollution is a mixture of solid particles and gaseous pollutants derived from fossil fuel combustion and vehicle exhaust. Previous research has linked ambient air pollution with the onset of autoimmune diseases. This study aims to investigate the relationship between air pollution exposure and the initiation of bDMARDs in patients newly diagnosed with rheumatoid arthritis (RA).

Methods: Data was obtained from NIH All of Us Research Program (v7). RA patients were identified by at least 3 inpatient or outpatient visits with ICD-9, ICD-10 or SNOMED codes of RA in the EHR. Participants who received RA diagnosis between January 1, 2008 and December 31, 2015 were included in this study. Cases were defined as RA patients who received bDMARDs including etanercept, adalimumab, infliximab, golimumab, certolizumab, abatacept, and tocilizumab within 1 year of RA diagnosis. For each case, 5 controls were matched based on sex, age of RA diagnosis, race/ethnicity, and disease duration. Ambient air pollution data for PM2.5, NO2 and O3 were sourced from NASA’s Socioeconomic Data and Applications Center (SEDAC)1-3. Exposure to air pollutants was estimated based on the participants’ 3-digit zip code at enrollment. To assess the potential impact of pollution over time, we calculated averages for 3-month, 6-month, 9-month, and 12-month periods prior to bDMARD initiation. Conditional logistic regression was conducted to evaluate the odds of bDMARD initiation in relation to per interquartile range (IQR) increase in air pollutant concentrations. To address possible correlations among air pollutants, we calculated Pearson correlation coefficients (r) for pollutant pairs.

Results: We identified 206 cases and 1030 controls (Table 1). The average PM2.5, NO2 and O3 concentrations during the month of bDMARD initiation were 8.91 ± 3.34 µg/m3, 20.69 ± 10.22 ppb and 37.32 ± 8.97 ppb, respectively. We found increased odds of bDMARD initiation per IQR increase in PM2.5 concentrations, with adjusted odds ratios (aORs) of 1.32 (95% CI 1.01 – 1.71) for the 3-month average, 1.63 (95% CI 1.21 – 2.18) for the 6-month average, 1.62 (95% CI 1.18 – 2.23) for the 9-month average, and 1.66 (95% CI 1.18 – 2.34) for the 12-month average. We also observed a negative relationship between O3 concentrations and bDMARD initiation, with aORs of 0.68 (95% CI 0.55 – 0.85) for the 3-month average, 0.66 (95% CI 0.52 – 0.83) for the 6-month average, 0.54 (95% CI 0.41 – 0.72) for the 9-month average, and 0.54 (95% CI 0.41 – 0.70) for the 12-month average. No association was found between NO2 exposure and bDMARDs initiation (Table 2). There was a modest positive correlation between PM2.5 and NO2 (r = 0.32) and weak negative correlations between PM2.5 and O3 (r = -0.17), as well as NO2 and O3 (r = -0.23) (Table 3). 

Conclusion: Our study suggests that higher PM2.5 levels are associated with increased bDMARD initiation in newly diagnosed RA patients, while higher O3 levels are linked to decreased initiation. The associations were consistent across various exposure periods. Further studies on larger cohorts are needed to confirm the results. 

Reference: 1. Di, Environ Int. 2019; 2. Di, Environ Sci Technol. 2020; 3. Requia, Environ Sci Technol. 2020

Supporting image 1

Table 1: Demographic Information of Cases and Matched Controls

Supporting image 2

Table 2: Adjusted Odds Ratios for bDMARD Initiation per Interquartile Range (IQR) Increase in Air Pollutant Concentrations

Supporting image 3

Table 3: Correlation Coefficients for the Estimates of Air Pollutant Concentrations


Disclosures: J. Zheng: None; N. Barjaktarovic: None; L. lu: None.

To cite this abstract in AMA style:

Zheng J, Barjaktarovic N, lu L. Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/ambient-air-pollution-and-initiation-of-bdmards-in-newly-diagnosed-rheumatoid-arthritis-a-nested-case-control-study-of-nih-all-of-us-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ambient-air-pollution-and-initiation-of-bdmards-in-newly-diagnosed-rheumatoid-arthritis-a-nested-case-control-study-of-nih-all-of-us-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology